相关实验视频
Updated: May 28, 2025

07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
84.6K
低氧诱导因子酸酶抑制剂的心血管毒性:基于JADER数据库的不成比例性分析
Danna Wu1, Ting Xie2, Shuxin Jiao3
1Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, Hainan, China.
Expert opinion on drug safety
|February 9, 2025
概括
低氧诱导因子酸酶抑制剂 (HIF-PHI) 对贫血有希望,但具有心血管风险. 现实世界的数据分析揭示了与栓塞事件,心力衰竭和缺血性心脏病的关联,突出了需要警监测的必要性.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管安全心血管安全
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 低氧诱导因子酸酶抑制剂 (HIF-PHI) 是对贫血的新兴疗法.
- 有关与HIF-PHI治疗相关的潜在心血管毒性存在担忧.
研究的目的:
- 通过使用真实世界的安全数据,调查与HIF-PHI相关的心血管毒性.
- 评估HIF-PHI在治疗贫血中的安全性.
主要方法:
- 使用报告几率比率 (ROR) 和信息组件 (IC) 的不成比例分析.
- 数据来源于日本药物不良事件报告 (JADER) 数据库 (2020年1月至2023年9月).
主要成果:
- 对253599个不良事件的分析确定了4015个与HIF-PHI相关的病例,其中1537 (38.28%) 涉及心血管毒性.
- 对HIF-PHI的积极安全信号包括栓塞/血栓事件 (ROR=6.66),心力衰竭 (ROR=3.86),以及缺血性心脏病 (ROR=3.37).
- 高血压发病的中位时间为15.50天.
结论:
- HIF-PHI与多种心血管毒性有关.
- 加强对HIF-PHI相关心血管毒性的监测对于安全管理脏贫血至关重要.
相关概念视频
Hypoxia
866
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
866
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Pulmonary Hypertension: Classification and Pathogenesis
147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
147
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
460
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
460

